Dashboard|GLUE – Overview

GLUE

Monte Rosa Therapeutics, Inc.

Healthcare • CIK: 0001826457

Market Cap

$609.09M

P/E (TTM)

29.1x

Rev Growth (TTM)

+1112.3%

Net Margin (TTM)

11.5%

FCF Yield (TTM)

23.8%

FCF Margin (TTM)

79.9%

LATEST EARNINGS

•

Q3 2025

•

4 months ago

•View source

Revenue

$12.77M

+38.5%

Net Income

$-27.08M

-13.5%

EPS

—

•Announced a second collaboration with Novartis to develop novel degraders for immune-mediated diseases, receiving an upfront payment of $120 million and eligibility for up to $5.7 billion in total deal value.
•Phase 1 study of NEK7-directed MGD MRT-8102 is underway, with initial data readout including high-CVD risk cohort on track for H1 2026.
•VAV1-directed MGD MRT-6160 is advancing toward anticipated initiation of multiple Phase 2 studies in immune-mediated diseases.
•Phase 1/2 study of GSPT1-directed MGD MRT-2359 is advancing in mCRPC patients, with additional results expected by year-end.

View Full Earnings →

Cash Flow Health

Free Cash Flow3/8 positive

TTM$145M

Q3 '25

$100M+374%

Q2 '25

$-36M+23%

FCF Margin

TTM79.9%

Q3 '25781.5%+598%

Sector: 0.0%Top 10%

OCF Margin82.2%

OCF/NI7.12x

CapEx Coverage36.2x

FCF Yield23.8%

FCF Growth (2Y)–

Cash Conversion Cycle

0 days

DSO: 0+DIO: –−DPO: –

View Insights from Latest Filing →View Full Cash Flow Statement →

Capital Allocation & Returns

Total Shareholder Yield

TTM0.0%

Div Yield0.0%

Insufficient data

Dividend & Payout Metrics

Dividend Yield (TTM)0.0%

Free Cash Flow (TTM)$145.0M

Capital Return / FCF0.0%

Est. Dividends Paid (TTM)$0

Shows how management rewards shareholders

Operational Efficiency & Returns

Return on Invested CapitalTTM

2.6%

Volatile

+61.9%

P25MedianP75

75th pctl (med: 0.0%)

DuPont BreakdownROIC = Margin × Turn × (1+D/E)

NOPAT Margin

4.5%

Asset Turnover

0.46x

8Q: 0.12x

Leverage (1+D/E)

1.00x

D/E: 0.00x

DuPont: 2.1% ≈ 2.6% ROIC

Asset & CapEx Efficiency

Fixed Asset Turn

6.19x

8Q:1.47x

+564.1%

Invested Cap Turn

0.58x

8Q:0.14x

+52.3%

CapEx Intensity

1.3%

8Q:2.1%

CapEx/Depreciation

0.50x

Asset-based ROIC formula

Full Analysis

QUARTERLY TRENDS

Last 8 quarters + TTM

Metric	TTM	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023
Revenue	$181.5M	$12.8M↓45.0%	$23.2M↓72.7%	$84.9M↑40.0%	$60.6M↑558.1%	$9.2M↑96.3%	$4.7M↑341.3%	$1.1M	$0
Operating Income	$8.5M	$-33.0M↓112.0%	$-15.6M↓135.3%	$44.0M↑238.6%	$13.0M↑149.0%	$-26.5M↑18.7%	$-32.6M↑6.6%	$-34.9M↓0.2%	$-34.9M
Net Income	$20.9M	$-27.1M↓120.3%	$-12.3M↓126.2%	$46.9M↑248.9%	$13.4M↑156.3%	$-23.9M↑21.3%	$-30.3M↑5.2%	$-32.0M↑3.9%	$-33.3M
Operating Cash Flow	$149.1M	$100.4M↑389.3%	$-34.7M↑23.7%	$-45.5M↓135.3%	$128.9M↑714.1%	$-21.0M↑24.4%	$-27.8M↑27.2%	$-38.2M↓228.8%	$29.6M
Free Cash Flow	$145.0M	$99.8M↑374.0%	$-36.4M↑22.7%	$-47.1M↓136.6%	$128.7M↑701.8%	$-21.4M↑28.2%	$-29.8M↑24.7%	$-39.5M↓241.5%	$27.9M
Total Equity	N/A

Income Statement Cash Flow Statement Balance Sheet

Valuation Analysis

Fair Value

Price-to-EarningsTTM

29.1x

Volatile

8Q: -12.6x-828%

Valuation Lenses

Earnings

29.1x

vs – sector

Cash Flow

2.7x

EV/FCF vs –

Growth-Adj

0.0xPEG

Undervalued for growth

Quality-Adj

11.2P/E per %ROIC

ROIC: 2.6%

Shareholder Returns

Dividend

–

Buyback

–

Total Yield

–

Market Cap$609.09M

EV$393.09M

Multi-angle valuation analysis with sector context

Business Quality & Moat

Overall Quality Score

41/100

Average

Composite score: Returns (40%) + Consistency (30%) + Earnings Quality (30%)

Returns on Capital

Return on Equity (ROE)Above Avg

8.4%

8Q:–

Return on Invested Capital (ROIC)Top 25%

2.6%

8Q:–

+61.9%

DuPont Analysis (ROIC = NOPAT Margin × Asset Turnover)

NOPAT Margin: 4.5%

Asset Turnover: 0.46x

Earnings Quality

Cash Conversion

7.12x

OCF / Net Income ✓

FCF Consistency

–

Positive quarters

Competitive Moat Indicators

Pricing Power

Gross Margin–

Capital Efficiency

Invested Capital Turnover0.58x

Working Capital

Cash Conversion Cycle0 days

Growth Quality & Momentum

Moderate Growth

Growth Quality Score

70/100

Growth 40%

Margins 30%

FCF 20%

Consistency 10%

Growth Rates

Revenue Growth YoY

1112.3%

OpInc Growth YoY

-24.3%

EPS Growth YoY

N/A

FCF 3Y CAGR

N/A

Margin Quality & Sustainability

Low Quality

Profitability Cascade

Gross

—

Operating

4.7%

Above Avg in sector

Net

11.5%

Margins Unknown

Earnings Quality Signals

SBC / Revenue

—

FCF vs Net Gap

+68.3 pts

FCF: 79.9% | Net: 11.5%

Quality = stability + cash conversion + low dilution

Balance Sheet & Solvency

Fortress

Net Debt / EBITDA

Net Cash

(0.0x)Net Cash: $391.30M

Interest Coverage

–

+Net cash position: $391.30M

Leverage Metrics

Debt-to-Equity

0.00x

Balance sheet risk & solvency analysis